FY2026 Earnings Estimate for IONS Issued By Leerink Partnrs

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) – Stock analysts at Leerink Partnrs reduced their FY2026 earnings per share estimates for shares of Ionis Pharmaceuticals in a report issued on Monday, February 24th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings per share of ($3.25) for the year, down from their prior estimate of ($3.24). The consensus estimate for Ionis Pharmaceuticals’ current full-year earnings is ($3.50) per share. Leerink Partnrs also issued estimates for Ionis Pharmaceuticals’ FY2027 earnings at ($1.62) EPS.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its quarterly earnings results on Wednesday, February 19th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.46. Ionis Pharmaceuticals had a negative return on equity of 100.05% and a negative net margin of 64.25%. The firm had revenue of $227.00 million during the quarter, compared to analyst estimates of $140.97 million. During the same period last year, the company earned $0.12 EPS. Ionis Pharmaceuticals’s quarterly revenue was down 30.2% compared to the same quarter last year.

IONS has been the subject of a number of other reports. StockNews.com lowered Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, November 12th. Royal Bank of Canada reissued an “outperform” rating and set a $70.00 price target on shares of Ionis Pharmaceuticals in a research note on Thursday, February 20th. Wells Fargo & Company decreased their target price on Ionis Pharmaceuticals from $82.00 to $77.00 and set an “overweight” rating for the company in a research report on Thursday, November 7th. William Blair reaffirmed an “outperform” rating on shares of Ionis Pharmaceuticals in a research report on Friday, December 20th. Finally, Piper Sandler decreased their target price on Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating for the company in a research report on Thursday, November 14th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Ionis Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $60.00.

Ionis Pharmaceuticals Price Performance

Shares of IONS stock opened at $31.76 on Thursday. Ionis Pharmaceuticals has a 52-week low of $30.23 and a 52-week high of $52.34. The company has a debt-to-equity ratio of 2.12, a quick ratio of 8.82 and a current ratio of 8.47. The firm has a market capitalization of $5.05 billion, a P/E ratio of -10.45 and a beta of 0.34. The stock has a 50 day moving average price of $33.32 and a 200 day moving average price of $37.98.

Insider Buying and Selling

In other news, CEO Brett P. Monia sold 33,445 shares of the stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $32.63, for a total value of $1,091,310.35. Following the transaction, the chief executive officer now directly owns 207,396 shares of the company’s stock, valued at approximately $6,767,331.48. This represents a 13.89 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Patrick R. O’neil sold 6,165 shares of the stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $31.62, for a total value of $194,937.30. Following the completion of the transaction, the executive vice president now directly owns 57,452 shares in the company, valued at $1,816,632.24. This represents a 9.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 111,816 shares of company stock worth $3,603,914 in the last ninety days. 2.71% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of IONS. Capital World Investors increased its holdings in shares of Ionis Pharmaceuticals by 46.5% in the fourth quarter. Capital World Investors now owns 11,465,413 shares of the company’s stock valued at $400,831,000 after purchasing an additional 3,637,041 shares during the period. Norges Bank acquired a new position in shares of Ionis Pharmaceuticals in the fourth quarter valued at about $59,948,000. Vanguard Group Inc. increased its holdings in shares of Ionis Pharmaceuticals by 9.4% in the fourth quarter. Vanguard Group Inc. now owns 16,472,539 shares of the company’s stock valued at $575,880,000 after purchasing an additional 1,416,781 shares during the period. Vestal Point Capital LP acquired a new position in shares of Ionis Pharmaceuticals in the fourth quarter valued at about $20,801,000. Finally, Orbimed Advisors LLC increased its holdings in shares of Ionis Pharmaceuticals by 21.2% in the fourth quarter. Orbimed Advisors LLC now owns 2,817,347 shares of the company’s stock valued at $98,494,000 after purchasing an additional 492,900 shares during the period. 93.86% of the stock is owned by institutional investors and hedge funds.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.